A higher proportion of patients achieved at least a 3-point difference in the QMG score with zilucoplan compared with placebo, although this difference did not reach statistical significance.
← all excerpts
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
1
—
—